Free press releases distribution network?

Agency / Source: ECON Corporate Services / InvestorIdeas.com™

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Aethlon Medical, Inc. Announces Hepatitis-C Clinical Trial Site - Aethlon Medical, Inc. announced today that Qualtran LLC,  has advised the Company that the Apollo Hospital, New Delhi has been retained as a sponsor site for Aethlon's forthcoming Hepatitis-C (HCV) clinical trials in India.
Aethlon Medical, Inc. Announces Hepatitis-C Clinical Trial Site

 

PRZOOM - /newswire/ - San Diego, CA, United States, 2005/06/09 - Aethlon Medical, Inc. announced today that Qualtran LLC, has advised the Company that the Apollo Hospital, New Delhi has been retained as a sponsor site for Aethlon's forthcoming Hepatitis-C (HCV) clinical trials in India..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Aethlon Medical, Inc. (OTCBB: AEMD) announced today that Qualtran LLC, a contract research organization (CRO) managing biocompatibility studies and clinical trials for Aethlon in India, has advised the Company that the Apollo Hospital, New Delhi has been retained as a sponsor site for Aethlon's forthcoming Hepatitis-C (HCV) clinical trials in India. "The Apollo Hospital is undisputedly the most prestigious multi-specialty hospital in India and is the largest corporate hospital outside of the United States," stated Mr. Sandeep Malik, President of Qualtran.

Dr. Vijay Kher, Senior Consultant of Nephrology at Apollo Hospital has been retained as the Principal Investigator for the trial. Dr. Kher, who has over 30 years of clinical experience, has been the recipient of numerous medical awards, and is credited with over 100 scientific publications. Following a Clinical and Research fellowship at Henry Ford Hospital, Detroit and the University of Cincinnati, Dr. Kher served as a visiting professor to several Universities, including the University of Cincinnati, Loyola University, Rutgers, and the University of Chicago.

Aethlon Chairman & CEO, James A. Joyce, stated, "The unfortunate reality is that 50% of Hepatitis-C patients who initiate the current standard of care fail this exceptionally toxic treatment regimen." Joyce continued, "We clearly envision that our Hemopurifier(TM) treatment technology will improve patient outcomes as an adjunctive therapy, and will serve as an effective disease management tool as a stand alone treatment. In this regard, I thank our colleagues in India for providing us the opportunity to treat patients who are infected with this progressive disease," concluded Joyce.

Aethlon further disclosed that biocompatibility studies of the Hemopurifier are under way, and the Company anticipates that the formal initiation of the trial will occur in mid-July. The near term goal will be to demonstrate safety and observe early efficacy markers, including viral load reduction as a result of the direct clearance of circulating HCV by the Hemopurifier. The patient treatment protocols developed for the trial were designed through a cooperative effort between Aethlon researchers and its regulatory advisors in both India and the United States. According to the World Health Organization, HCV is a global disease with approximately 170 million persons or 3% of the world's population infected.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to treat drug and vaccine resistant pathogens. The market focus is the treatment of the Human Immunodeficiency Virus (HIV), Hepatitis-C (HCV), and Biological Weapon candidates. Aethlon has an experienced management team, which receives support and guidance from globally recognized science advisors representing the infectious disease, biowarfare, and dialysis industries. Clinical Trials to treat HIV and HCV patients in India are scheduled to begin in the coming months, and U.S. clinical studies are expected to begin later this year. More information on Aethlon Medical and the Hemopurifier technology is available at aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Source: Aethlon Medical, Inc.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: ECON Corporate Services / InvestorIdeas.com™

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Aethlon Medical, Inc. Announces Hepatitis-C Clinical Trial Site

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Anne Hoversten 
858-459-7800
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ECON Corporate Services / InvestorIdeas.com™ securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From ECON Corporate Services / InvestorIdeas.com™ / Company Profile


Read Medical Services/Equipment Most Recent Related Press Releases:

Frost & Sullivan Lauds SnooZeal’s Unique Electrical Stimulation Therapy for Sleep Apnea in the European Market
ZOLL Expands the Rescuer Experience at EMS Today
Traditional Mass Spectrometers Give Way to High-resolution Technologies Such as MALDI-TOF Finds Frost & Sullivan
AccuVein, Inc. Named A Best Place to Work in Medical Sales for Second Consecutive Year
Ansell Limited Acquires Cleanroom and Healthcare Consumables Manufacturer Nitritex Limited
ZOLL to Showcase Expanded Portfolio of Advanced Resuscitation and Acute Critical Care Technologies at Arab Health 2017
Frost & Sullivan Awards Ansell for Entrenching itself in the Hand Protection Market with its Visionary Products and Technologies
ZOLL RescueNet ePCR Achieves Latest National Compliance Standard
Eye Tech Care Wins Top Honours from Frost & Sullivan for Developing the EyeOP1, the Only Computer-assisted System for Glaucoma Therapy
Frost & Sullivan Recognizes Nuvectra’s Pioneering Spinal Cord Stimulation Product for Chronic Pain Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today